Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | SIRT7 | Q9NRC8 | 1/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 7/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.41 |
| ▸ | TYMS | P04818 | 2/20 | 0.39 |
| ▸ | GART | P22102 | 2/20 | 0.39 |
| ▸ | ATIC | P31939 | 2/20 | 0.39 |
| ▸ | FURIN | P09958 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153605 | 0.85 | SIRT2 (0.53) | SIRT2SIRT1SIRT3SIRT6SIRT7 | |
| SCHEMBL3651453 | 0.72 | NOD1 (0.55) | FOLH1 | |
| SCHEMBL17304349 | 0.70 | NOD1 (0.52) | FOLH1 | |
| SCHEMBL17304352 | 0.70 | NOD1 (0.52) | FOLH1 | |
| SCHEMBL17304342 | 0.70 | NOD1 (0.52) | FOLH1 | |
| SCHEMBL17304354 | 0.70 | NOD1 (0.52) | FOLH1 | |
| SCHEMBL17304345 | 0.70 | NOD1 (0.52) | FOLH1 | |
| SCHEMBL17304348 | 0.70 | NOD1 (0.52) | FOLH1 | |
| SCHEMBL17304347 | 0.70 | NOD1 (0.52) | FOLH1 | |
| SCHEMBL17304355 | 0.70 | NOD1 (0.52) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538157-B1 | METHYLGLYOXAL-SCAVENGING CYCLIC PEPTIDES AND THEIR USE FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH ELEVATED METHYLGLYOXAL LEVELS | RUPRECHT KARLS UNIV (DE) | 2022-05-18 | — | — | EP | disclosed |
| US-11202833-B2 | Methylglyoxal-scavenging cyclic peptides and their use for the prevention and treatment of diseases associated with elevated methylglyoxal levels | Ruprecht-Karls-Universität Heidelberg (DE) | 2021-12-21 | — | — | US | disclosed |
| US-20190282700-A1 | METHYLGLYOXAL-SCAVENGING CYCLIC PEPTIDES AND THEIR USE FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH ELEVATED METHYLGLYOXAL LEVELS | Ruprecht-Karls-Universität Heidelberg (DE) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11202833-B2 | Methylglyoxal-scavenging cyclic peptides and their use for the prevention and treatment of diseases associated with elevated methylglyoxal levels | PTMS, GLO1, ARGLU1 | SIRT2 576/4885SIRT1 183/4885SIRT3 260/4885 |
| US-20190282700-A1 | METHYLGLYOXAL-SCAVENGING CYCLIC PEPTIDES AND THEIR USE FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH ELEVATED METHYLGLYOXAL LEVELS | PTMS, GLO1, ARGLU1 | SIRT2 576/4885SIRT1 183/4885SIRT3 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.